A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-4482 in Healthy Participants Inoculated With Experimental Influenza Virus
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Molnupiravir (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 11 Jul 2024 Status changed from active, no longer recruiting to completed.
- 31 May 2024 Status changed from recruiting to active, no longer recruiting.
- 18 Mar 2024 Planned End Date changed from 29 Mar 2024 to 28 Jun 2024.